文献速递神经介入DSA

颅内动脉瘤患者使用Pipeline栓塞装置治疗的临床与血管造影结局:随着术者在装置释放和患者管理方面经验增加,术中技术困难、主要并发症和神经性死亡显著减少

Clinical and angiographic outcomes in patients with intracranial aneurysms treated with the pipeline embolization device: intra-procedural technical difficulties, major morbidity, and neurological mortality decrease significantly with increased operator experience in device deployment and patient management.
PubMed 文献 · Neuroradiology · 2017-10-06

回顾性分析两个中心4.5年内140例患者150次Pipeline手术治疗的167个颅内动脉瘤,比较前75次与后75次手术,术中技术困难(13.3% vs 2.7%,p=0.03)及主要并发症与神经性死亡合计(14.7% vs 4%,p=0.046)在后75次显著降低;末次随访81.5%动脉瘤完全闭塞(平均24个月)。

要点

  • 前75次手术术中技术困难13.3%,后75次降至2.7%(p=0.03)。
  • 前75次主要并发症与神经性死亡合计14.7%,后75次降至4%(p=0.046)。
  • 末次随访81.5%动脉瘤完全闭塞,平均随访24个月。

核心结论

  • Pipeline栓塞装置是颅内动脉瘤的有效治疗方法;随着术者在Pipeline释放和患者管理方面经验增加,术中技术困难及主要并发症与神经性死亡合计的风险显著降低。

研究设计与样本

  • 回顾性研究,两个中心4.5年期间140例患者、150次Pipeline手术、167个颅内动脉瘤;分析基线患者与动脉瘤特征、并发症及血管造影结局。

诊断标准与关键数值

  • 末次随访123个动脉瘤完全闭塞(81.5%,平均24个月);5个动脉瘤再次治疗(3.3%);年龄≤53岁为末次随访完全闭塞的独立预测因素(p=0.001,OR 0.92,95%CI 0.88-0.97)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Flow diversion constitutes a pivotal advancement in endovascular intracranial aneurysm treatment, but requires development of a new skill set. The aim of this study is to determine whether outcomes after treatment with the Pipeline Embolization Device improve with experience.

METHODS: We retrospectively reviewed all patients with intracranial aneurysms treated with Pipeline at two centers over a 4.5-year period. Baseline patient and aneurysm characteristics, complications, and angiographic outcomes were analyzed.

RESULTS: One hundred forty patients underwent 150 Pipeline procedures to treat 167 intracranial aneurysms during the study period, 109 women, mean age 55.4 years. One hundred twenty-six aneurysms were ICA, mean size 10.2 mm and mean neck 6.4 mm. Intra-procedural technical difficulties were higher during the first 75 procedures compared with the subsequent 75 (13.3 vs 2.7%; p = 0.03), as combined major morbidity and neurological mortality (14.7 vs 4%; p = 0.046). In multivariate regression analysis, increased operator experience with Pipeline remained an independent predictor of intra-procedural technical difficulties (p = 0.02, odds ratio (OR) 0.015, 95% CI 0.0004-0.55) and combined major morbidity and neurological mortality (p = 0.03, OR 0.16, 95% CI 0.03-0.84). At last follow-up, 123 aneurysms were completely occluded (81.5%, mean 24 months). In our cohort, age ≤ 53 years was an independent predictor of complete aneurysm occlusion at last follow-up (p = 0.001, OR 0.92, 95% CI 0.88-0.97). Five aneurysms were retreated (3.3%).

CONCLUSION: The Pipeline embolization device is an effective treatment for intracranial aneurysms. The risk of intra-procedural technical difficulties and combined major morbidity and neurological mortality decreases significantly with increased operator experience in Pipeline deployment and patient management.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Delgado Almandoz JE, Kayan Y, Tenreiro A, et al. Clinical and angiographic outcomes in patients with intracranial aneurysms treated with the pipeline embolization device: intra-procedural technical difficulties, major morbidity, and neurological mortality decrease significantly with increased operator experience in device deployment and patient management. Neuroradiology. 2017. PMID: 28986614. doi:10.1007/s00234-017-1930-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。